Efficiency of tacrolimus therapy for perianal Crohn’s disease


Cite item

Full Text

Abstract

Aim. To determine the efficacy of 0.1% tacrolimus ointment in patients with perianal Crohn’s disease (CD). Subjects and methods. This prospective randomized trial enrolled 20 patients with perianal CD as anal fissures and rectal fistulas. The inclusion criteria were rectovaginal or extrasphincteric fistulas and purulent leakages. A study group comprised 11 patients, including 9 with anal fissures and 2 with fistulas. A control group included 9 patients, including 8 with fissures and 1 with fistulas. The study group received systemic therapy with azathioprine 2 mg/kg/day and tacrolimus ointment 2 mg/day; the control group had systemic therapy with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day. Control examination and perianal CD activity index (PCDAI) determination were done 6 and 12 weeks after therapy initiation. Results. At 6 weeks after beginning the study, local examination revealed the signs of anal fissure epithelialization in 5 (45.5%) of the 11 patients in the study group and in 3 (33.3%) of the 9 patients in the control one. At 12 weeks, fissure epithelialization and fistula obliteration were stated in 6 (54%) patients in the study group and in 3 (33%) of the 9 patients in the control group. At 12 weeks, PCDAI in the study and control groups was 2.00 and 4.44 scores (p=0.01). Conclusion. The findings suggest that topical 0.1% tacrolimus ointment versus antibacterial suppositories and hormone ointments is effective in treating patients with perianal CD. Topical 0.1% tacrolimus ointment therapy caused a reduction in PCDAI.

References

  1. Crohn B.B., Ginzberg L., Oppenheimer G.D. Regional ileitis: a pathologic and clinical entity. JAMA 1932; 99: 1323.
  2. Hellers G., Bergstrand O., Ewerth S. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980; 21 (6): 525—527.
  3. Sandborn W.J., Fazio V.W., Feagan B.G. et al. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003; 125 (5): 1508—1530.
  4. Schwartz D.A., Loftus E.V., Tremaine W.J. et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002; 122 (4): 875—880.
  5. Linares L., Moreira L.F., Andrews H. et al. Natural history and treatment of anorectal strictures complicating Crohn’s disease. Br J Surg 1988; 75 (7): 653—655.
  6. Penner A., Crohn B. Perianal fistulae as a complication of regional ileitis. Ann Surg 1938; 108: 867—873.
  7. McClane S.J., Rombeau J.L. Anorectal Crohn’s disease. Surg Clin North Am 2001; 81 (1): 169—183.
  8. Williams J.G., Rothenberger D.A., Nemer F.D. et al. Fistula-in-ano in Crohn’s disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991; 34 (5): 378—384.
  9. Halme L., Sainio A.P. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum 1995; 38 (1): 55—59.
  10. Sangwan Y.P., Schoetz D.J., Murray J.J. et al. Perianal Crohn’s disease. Results of local surgical treatment. Dis Colon Rectum 1996; 39 (5): 529—535.
  11. Faucheron J.L., Saint-Marc O., Guibert L. et al. Long-term seton drainage for high anal fistulas in Crohn’s disease — a sphincter-saving operation? Dis Colon Rectum 1996; 39 (2): 208—211.
  12. Pearl R.K., Andrews J.R., Orsay C.P. et al. Role of the seton in the management of anorectal fistulas. Dis Colon Rectum 1993; 36 (6): 573—577.
  13. Keighley M.R., Allan R.N. Current status and influence of operation on perianal Crohn’s disease. Int J Colorectal Dis 1986; 1 (2): 104—107.
  14. Lichtenstein G.R. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130 (3): 940—987.
  15. Dejaco C., Harrer M., Waldhoer T. et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003; 18 (11—12): 1113—1120.
  16. Colombel J.F., Lemann M., Cassagnou M. et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiquesdes Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674—678.
  17. Peyrin-Biroulet L., Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870—879.
  18. Madoff R.D., Fleshman J.W. AGA technical review on the diagnosis and care of patients with anal fissure. Gastroenterology 2003; 124 (1): 235—245
  19. Шелыгин Ю.А., Кашников В.Н, Болихов К.В. и др. Илеостомия и ее эффективность при осложненных формах БК толстой кишки. Колопроктология 2012; 3: 41—47.
  20. Stange E.F., Travis S.P.L., Vermeire S. et al. European evidence based guidelines on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006; 55: 16—35.
  21. Carter M.J., Lobo A.J., Travis S.P.L. British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: 1—16.
  22. Fleisher A.B. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroid therapy. J Allergy Clin Immunol 2000; 104: 62—66.
  23. Wollenberg A., Biber T.F.K. Tacrolimus in: Strategies for immunointerventions in Dermatology. Heiderberg: Springer-Verlag. 1997.
  24. Colombo M., Bochner B.S., Marone G. Human skin mast cells express functional betal integrins that mediate adhesion to extracellular matrix proteins. J Immunol 1995; 154: 6058—6064.
  25. Panhans-Gro A., Novak N., Kraft S. Human epidermal Largerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345—352.
  26. Leung D.Y.M., Soter N.A. Cellular and immunologic mechanisms in atropic dermatitis. J Am Acad Dermotol 2001; 44: S1—S12.
  27. Bieber T. Topical tacrolimus (FK506): a new milestone in the management of atopic dermatitis. N Engl J Med 1997; 337: 816—821.
  28. Jakobovits J., Schuster M.M. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984; 79: 533— 540.
  29. Fleshner P.R., Schoetz D.J., Roberts P.L. et al. Anal fissure in Crohn’s disease: a plea for aggressive management. Dis Colon Rectum 1995; 38 (11): 1137—1143.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies